Log in

NASDAQ:GOSSGossamer Bio Stock Price, Forecast & News

+0.05 (+0.41 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $12.15
50-Day Range
MA: $12.90
52-Week Range
Now: $12.15
Volume939,605 shs
Average Volume963,900 shs
Market Capitalization$806.27 million
P/E RatioN/A
Dividend YieldN/A
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications. It has license agreement with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:GOSS



Sales & Book Value

Annual SalesN/A
Book Value$4.62 per share


Net Income$-180,310,000.00


Market Cap$806.27 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive GOSS News and Ratings via Email

Sign-up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.

Gossamer Bio (NASDAQ:GOSS) Frequently Asked Questions

How has Gossamer Bio's stock been impacted by COVID-19 (Coronavirus)?

Gossamer Bio's stock was trading at $10.59 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GOSS shares have increased by 14.7% and is now trading at $12.15. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Gossamer Bio?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Gossamer Bio.

When is Gossamer Bio's next earnings date?

Gossamer Bio is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Gossamer Bio.

How were Gossamer Bio's earnings last quarter?

Gossamer Bio Inc (NASDAQ:GOSS) announced its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.87) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.80) by $0.07. View Gossamer Bio's earnings history.

What price target have analysts set for GOSS?

7 analysts have issued twelve-month price objectives for Gossamer Bio's shares. Their forecasts range from $21.00 to $36.00. On average, they anticipate Gossamer Bio's stock price to reach $29.29 in the next twelve months. This suggests a possible upside of 141.0% from the stock's current price. View analysts' price targets for Gossamer Bio.

Has Gossamer Bio been receiving favorable news coverage?

Press coverage about GOSS stock has trended very negative on Sunday, InfoTrie reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Gossamer Bio earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news aboutGossamer Bio.

Are investors shorting Gossamer Bio?

Gossamer Bio saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 4,730,000 shares, a decrease of 5.8% from the April 30th total of 5,020,000 shares. Based on an average daily volume of 403,500 shares, the short-interest ratio is currently 11.7 days. Currently, 10.8% of the shares of the company are sold short. View Gossamer Bio's Current Options Chain.

Who are some of Gossamer Bio's key competitors?

What other stocks do shareholders of Gossamer Bio own?

Who are Gossamer Bio's key executives?

Gossamer Bio's management team includes the following people:
  • Mr. Faheem Hasnain, Co-Founder & Exec. Chairman (Age 61)
  • Dr. Sheila K. Gujrathi M.D., Co-Founder, Pres, CEO & Director (Age 49)
  • Mr. Bryan Giraudo, Chief Financial Officer (Age 43)
  • Mr. Christian Waage, Exec. VP, Gen. Counsel & Sec. (Age 52)
  • Dr. Jakob Dupont, Chief Medical Officer (Age 54)

When did Gossamer Bio IPO?

(GOSS) raised $230 million in an initial public offering on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.

What is Gossamer Bio's stock symbol?

Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS."

Who are Gossamer Bio's major shareholders?

Gossamer Bio's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.29%), Alliancebernstein L.P. (2.77%), State Street Corp (2.50%), Federated Hermes Inc. (2.29%), Victory Capital Management Inc. (2.10%) and Victory Capital Management Inc. (2.10%). Company insiders that own Gossamer Bio stock include Bryan Giraudo, Faheem Hasnain, Fund V Gp LP Omega, Jakob Dupont, Luisa Salter-Cid, Russell J Cox and Waage Christian. View institutional ownership trends for Gossamer Bio.

Which major investors are selling Gossamer Bio stock?

GOSS stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Cormorant Asset Management LP, Ensign Peak Advisors Inc, BlackRock Inc., Russell Investments Group Ltd., UBS Group AG, Squarepoint Ops LLC, and Alps Advisors Inc.. Company insiders that have sold Gossamer Bio company stock in the last year include Fund V Gp LP Omega, Jakob Dupont, and Luisa Salter-Cid. View insider buying and selling activity for Gossamer Bio.

Which major investors are buying Gossamer Bio stock?

GOSS stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Victory Capital Management Inc., Victory Capital Management Inc., Morgan Stanley, Alyeska Investment Group L.P., Alliancebernstein L.P., Geode Capital Management LLC, and GSA Capital Partners LLP. Company insiders that have bought Gossamer Bio stock in the last two years include Bryan Giraudo, Faheem Hasnain, Russell J Cox, and Waage Christian. View insider buying and selling activity for Gossamer Bio.

How do I buy shares of Gossamer Bio?

Shares of GOSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Gossamer Bio's stock price today?

One share of GOSS stock can currently be purchased for approximately $12.15.

How big of a company is Gossamer Bio?

Gossamer Bio has a market capitalization of $806.27 million. The company earns $-180,310,000.00 in net income (profit) each year or ($3.29) on an earnings per share basis. Gossamer Bio employs 118 workers across the globe.

What is Gossamer Bio's official website?

The official website for Gossamer Bio is www.gossamerbio.com.

How can I contact Gossamer Bio?

Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The company can be reached via phone at 858-922-0718.

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.